Privium Fund Management B.V. 4 D Molecular Therapeutics, Inc. Transaction History
Privium Fund Management B.V.
- $469 Million
- Q2 2025
A detailed history of Privium Fund Management B.V. transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Privium Fund Management B.V. holds 197,458 shares of FDMT stock, worth $1.11 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
197,458
Previous 131,000
50.73%
Holding current value
$1.11 Million
Previous $423,000
73.05%
% of portfolio
0.16%
Previous 0.11%
Shares
7 transactions
Others Institutions Holding FDMT
# of Institutions
132Shares Held
43.7MCall Options Held
25.8KPut Options Held
33.4K-
Black Rock Inc. New York, NY4.9MShares$27.6 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.56MShares$25.7 Million0.31% of portfolio
-
Bvf Inc San Francisco, CA4.56MShares$25.7 Million0.65% of portfolio
-
Goldman Sachs Group Inc New York, NY4.17MShares$23.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.76MShares$15.5 Million0.0% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $182M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...